ALOPECIA AREATA

This study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …

This early-stage study tests a new medicine called DR-01 in 81 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to…

This study tests a drug called bempikibart (ADX-914) in 75 adults with severe alopecia areata, a condition causing significant scalp hair loss. In the first part, some participants received the drug and some a placebo to see if it helps hair regrow. The second part gives the drug…

This study tests an experimental drug called rezpegaldesleukin in 94 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants receive either the drug or a placebo for 36 weeks, with an optional extension. The main goal is to measu…

This study monitors the long-term safety and effectiveness of the drug Litfulo (ritlecitinib) in 487 patients with alopecia areata, a condition causing patchy hair loss. Researchers will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 o…

This study compares two treatments for alopecia areata, a condition causing patchy hair loss. One group receives microneedling alone, while the other gets microneedling plus topical vitamin D3. The goal is to see if adding vitamin D3 leads to complete hair regrowth. Eighty adults…

This study looks at the long-term safety and effectiveness of a drug called CTP-543 for adults with moderate to severe alopecia areata, a condition that causes patchy hair loss. About 1,000 people who already completed 24 weeks of treatment in a previous CTP-543 trial will contin…

This study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …

This study looks at how well the drug ritlecitinib works for people with severe alopecia areata (a condition causing patchy or total hair loss) in real-world settings, not just in controlled trials. Researchers will review medical records of about 300 patients aged 12 and older w…

This observational study examines whether certain blood markers (VEGF-A and VCAM-1) are linked to nailfold capillary changes in people with alopecia areata. Researchers will compare 90 participants (patients with acute or chronic alopecia areata and healthy volunteers) using bloo…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …